METHOD OF TREATING HYPOGONADOTROPIC HYPOGONADISM, NASAL SPRAY AS METHOD FOR ADMINISTERING PEPTIDE COMPLEX "MH-GNDR-19-21" IN TREATING HYPOGONADOTROPIC HYPOGONADISM Russian patent published in 2024 - IPC A61K38/00 A61K31/405 A61P5/00 A61K47/18 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to a method of treating hypogonadotropic hypogonadism, which consists in administering an intranasal spray in dosage of 1 to 20 mcg in a pulsed mode simulating physiological secretion, where the intranasal spray contains the peptide complex "MH-GNDR-19-21" and auxiliary additives, such as benzalkonium chloride, purified water, with the following content of components, wt %: peptide complex "MH-GNDR-19-21" 2.94, benzalkonium chloride 2.2, purified water—the rest, and wherein the peptide complex "MH-GNDR-19-21" contains, mcg: glycine 111.2, proline 82, arginine 133.5, leucine 95.5, tyrosine 137.7, serine 73.5, tryptophan 157.1, histidine 115.7, pyroglutamic acid 93.8, also relates to an intranasal spray in the treatment of hypogonadotropic hypogonadism, containing a peptide complex "MH-GNDR-19-21" and auxiliary additives such as benzalkonium chloride, purified water, with the following content of components, wt %: peptide complex "MH-GNDR-19-21" 2.94, benzalkonium chloride 2.2, purified water—the rest, wherein peptide complex "MH-GNDR-19-21" contains, mcg: glycine 111.2, proline 82, arginine 133.5, leucine 95.5, tyrosine 137.7, serine 73.5, tryptophan 157.1, histidine 115.7, pyroglutamic acid 93.8.

EFFECT: group of inventions provides treating hypogonadotropic hypogonadism.

3 cl